A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a genomic biomarker of replication-stress is associa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/47ca4fa1fe9849e2a78a9dcd5d68a796
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:47ca4fa1fe9849e2a78a9dcd5d68a796
record_format dspace
spelling oai:doaj.org-article:47ca4fa1fe9849e2a78a9dcd5d68a7962021-12-02T17:27:12ZA Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer10.1038/s41467-021-25904-w2041-1723https://doaj.org/article/47ca4fa1fe9849e2a78a9dcd5d68a7962021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25904-whttps://doaj.org/toc/2041-1723A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a genomic biomarker of replication-stress is associated with outcome to gemcitabine alone and may predict which patients benefit from addition of the ATR inhibitor berzosertib.Panagiotis A. KonstantinopoulosAlexandre André B. A. da CostaDoga GulhanElizabeth K. LeeSu-Chun ChengAndrea E. Wahner HendricksonBose KochupurakkalDavid L. KolinElise C. KohnJoyce F. LiuElizabeth H. StoverJennifer CurtisNabihah TayobMadeline PolakDipanjan ChowdhuryUrsula A. MatulonisAnniina FärkkiläAlan D. D’AndreaGeoffrey I. ShapiroNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Panagiotis A. Konstantinopoulos
Alexandre André B. A. da Costa
Doga Gulhan
Elizabeth K. Lee
Su-Chun Cheng
Andrea E. Wahner Hendrickson
Bose Kochupurakkal
David L. Kolin
Elise C. Kohn
Joyce F. Liu
Elizabeth H. Stover
Jennifer Curtis
Nabihah Tayob
Madeline Polak
Dipanjan Chowdhury
Ursula A. Matulonis
Anniina Färkkilä
Alan D. D’Andrea
Geoffrey I. Shapiro
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
description A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a genomic biomarker of replication-stress is associated with outcome to gemcitabine alone and may predict which patients benefit from addition of the ATR inhibitor berzosertib.
format article
author Panagiotis A. Konstantinopoulos
Alexandre André B. A. da Costa
Doga Gulhan
Elizabeth K. Lee
Su-Chun Cheng
Andrea E. Wahner Hendrickson
Bose Kochupurakkal
David L. Kolin
Elise C. Kohn
Joyce F. Liu
Elizabeth H. Stover
Jennifer Curtis
Nabihah Tayob
Madeline Polak
Dipanjan Chowdhury
Ursula A. Matulonis
Anniina Färkkilä
Alan D. D’Andrea
Geoffrey I. Shapiro
author_facet Panagiotis A. Konstantinopoulos
Alexandre André B. A. da Costa
Doga Gulhan
Elizabeth K. Lee
Su-Chun Cheng
Andrea E. Wahner Hendrickson
Bose Kochupurakkal
David L. Kolin
Elise C. Kohn
Joyce F. Liu
Elizabeth H. Stover
Jennifer Curtis
Nabihah Tayob
Madeline Polak
Dipanjan Chowdhury
Ursula A. Matulonis
Anniina Färkkilä
Alan D. D’Andrea
Geoffrey I. Shapiro
author_sort Panagiotis A. Konstantinopoulos
title A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
title_short A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
title_full A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
title_fullStr A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
title_full_unstemmed A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
title_sort replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and atr inhibitor therapy in ovarian cancer
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/47ca4fa1fe9849e2a78a9dcd5d68a796
work_keys_str_mv AT panagiotisakonstantinopoulos areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT alexandreandrebadacosta areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT dogagulhan areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT elizabethklee areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT suchuncheng areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT andreaewahnerhendrickson areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT bosekochupurakkal areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT davidlkolin areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT eliseckohn areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT joycefliu areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT elizabethhstover areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT jennifercurtis areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT nabihahtayob areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT madelinepolak areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT dipanjanchowdhury areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT ursulaamatulonis areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT anniinafarkkila areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT alanddandrea areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT geoffreyishapiro areplicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT panagiotisakonstantinopoulos replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT alexandreandrebadacosta replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT dogagulhan replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT elizabethklee replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT suchuncheng replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT andreaewahnerhendrickson replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT bosekochupurakkal replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT davidlkolin replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT eliseckohn replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT joycefliu replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT elizabethhstover replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT jennifercurtis replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT nabihahtayob replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT madelinepolak replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT dipanjanchowdhury replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT ursulaamatulonis replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT anniinafarkkila replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT alanddandrea replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
AT geoffreyishapiro replicationstressbiomarkerisassociatedwithresponsetogemcitabineversuscombinedgemcitabineandatrinhibitortherapyinovariancancer
_version_ 1718380784701669376

Ejemplares similares